

Associations between ICU-days and patient experiences and perceptions of clinical research in intensive care units: a mediation analysis

Ming Guan¹

¹ Xuchang University

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.

Abstract

Background: Clinical research is responsible for high-quality therapy in intensive care units (ICU). Patient experiences and perceptions are an integral part of the clinical research, but little is known about relationship between them. The objective of this study is to describe critically ill patient experiences and perceptions of clinical research in ICU.

Methods: Data were collected from 344 patients from 15 UK ICUs. A total of 344 critically ill patients (ICU-days: 0 day, 36.63%; 1 or more, 63.37%) completed the survey. Significant differences in the patient experiences and perceptions of clinical research in ICU were depicted with t test. The factor structures of patient experiences and perceptions of clinical research in ICU were explored by exploratory structural equation modeling and principal component analysis. Associations between socioeconomic factors and patient experiences and perceptions were explored with logistic regressions. Mediation analyses among patient experiences, patient perceptions, ICU-days, informed participation were performed with structural equation modeling.

Results: Most patients were males (56.31%). The factor structures of patient experiences and perceptions of clinical research in ICU were five and four, respectively. There were high proportions of good experiences and poor perceptions in the sample. Significant differences were observed in the patient perceptions of clinical research regarding informed participation in ICU. Patients with informed participation were less likely to have poor patient perceptions than without (OR: 0.46, 95% CI: 0.29-0.74). The relationship of ICU-days→informed participation was mediated moderated by age groups and gender. There were no significant mediation and moderation effects among informed participation, patient experiences, and patient perceptions.

Conclusions: Our study offers several new insights regarding the role of informed participation in clinical research in patient experiences and perceptions in ICU. In addition, the findings suggest clinical research may benefit from socioeconomic factors of patients. Findings provide a basis for reflection on practice for specialist nurses, research teams, policymakers, and all with an interest in improvement in patient experiences and perceptions.

Keywords: Clinical research, Patient experiences, Patient perceptions, ICU-days, Informed participation

Ming Guan^{1,2,3}

¹ *Family Issues Center, Xuchang University, Xuchang, Henan, China*

² *International Issues Center, Xuchang University, Xuchang, Henan, China*

³ *School of Business, Xuchang University, Xuchang, Henan, China*

Corresponding author's email address: gming0604@163.com

Telephone number: 86+13409360114

Postal address: Road Bayi 88, Xuchang, Chin

Background

There has been an increase in the number of clinical research as result of the globalization trend^{[1][2]}. Clinical research brings lasting benefits to health systems^[3], establishes new treatments^[4], derives a valid and meaningful scientific conclusion^[5], and is primarily motivated by personal benefit^[6]. Facilitators and barriers of participation in HIV^{[7][8][9]}, pediatric^[10], gerontological^[11] clinical research were reported. Barriers to participation in COVID-19^[12], Alzheimer's^[13], diabetes^[14] clinical research were reported. Often facing vexing dilemmas in critically ill patients, intensive care unit becomes an idealized place to embark on clinical research.

Regarding informed participation in clinical research, some factors negatively affect potential participants' understanding of clinical research included long informed consent forms^[15] and misconceptions^[16]. Some facilitators included altruistic reasons^[17] and patient portals^[18] to clinical research. There are cross-cultural differences of provisions on informed consent in clinical research in Germany, Poland, and Russia^[19]. It is widely accepted and recognised that participant recruitment/invitations^[20], inappropriate payment for participation in clinical research^[21] sought to identify barriers to clinical research study. An early study explained the effect of race identity on intention to participate in clinical research^[22]. But, little knowledge about other socioeconomic factors was reported.

Globally, the perceptions and attitudes towards clinical research were reported among the general public in Qatar^[23], India^[24], and Mauritius^[25]. Patients' perspectives on clinical research were thought as useful and effective in older adults^[26]. Attitudes and expectations of clinical research participants toward digital health and mobile dietary assessment tools were documented^[27]. Participation in clinical trials positively influences the perception that participants have about pharmaceutical clinical research when compared to nonparticipants^[28]. Therefore, poor perceptions in clinical research should be prevented.

Regarding ICU patient experiences, anxiety^[29], stress^[30], antimicrobial resistance^[31], low and restricted self-determination^[32], shortage in nutrition support^[33], pain conditions^[34] were observed. Clinical research can benefit from patient perspectives to inform trial design. Some factors influencing study design of clinical research have been previously

reported. These factors included chairpersons' views in research ethics committees [35], suicide risk [36], ethical challenges [37][38][39].

The objective of the study was to assess ICU-days and patient experiences and perceptions of clinical research in intensive care units. This study hypothesized that associations between ICU-days and patient experiences and perceptions were mediated and moderated by analyses. With a publicly available survey data, this study would explore the factor structures of patient experiences and perceptions, mediating and moderating effect of socioeconomic factors in the relationship of ICU-days → informed participation, mediating and moderating effect of patient perceptions in the relationship of informed participation → patient experiences, and mediating and moderating effect of patient experiences in the relationship of informed participation → patient perceptions.

Methods

Data source

Data collection was from 1 September 2016 to 31 May 2020 by the Project titled “The Perspectives Study: From evidence to guidance on patient recruitment to clinical research in intensive care units (<https://reshare.ukdataservice.ac.uk/854286/>)” [40]. An ethical analysis led to the development of good practice guidance to enhance recruitment and consent processes for research in ICUs. Patients, relatives, and ICU staff were given separate versions of the survey. Each version included the same questions, with wording changed to reflect the respondents. Among the available 344 participants, surveyed sites were distributed as 1 (31.69%), 2 (2.33%), 3 (6.40%), 4 (14.24%), 5 (7.85%), 6 (3.20%), 7 (11.63%), 8 (4.07%), 10 (3.20%), 11 (4.07%), 12 (2.91%), 13 (5.52%), 14 (1.16%), and 15 (1.74%).

Main variables

Socioeconomic factors

The age options originally were distributed as 18-24, 25-34, 35-44, 45-54, 55-64, and 65-74 years. For statistical convenience, age options were integrated into young (18-34), middle (35-54), and old (55+) group. As for gender, the answers were male, female, and other. Here, the option “other” was considered as missing values. ICU-days was reflected by the question: “How long was your stay in the Intensive Care Unit (ICU)?” the response was a continuous variable from 0 to 70. For statistical convenience, ICU-days was categorized into groups: 0 and 1 or more.

Informed participation

Participation was reflected by the question: “Do you remember being asked to take part in a clinical research study in the ICU?” The response options were yes (=1), no (=2) and unsure (=3). Here, the response options of no (=2) and unsure (=3) were recoded as no (=0).

Patient experience of clinical research

Items of experience of clinical research studies in the ICU could be seen in Table 1. Response options were missing (=0), strongly disagree (=1), disagree (=2), neither agree nor disagree (=3), agree (=4), and strongly agree (=5). The reliability index of Experience of clinical research studies in the ICU in this sample is excellent ($\alpha = 0.9833$).

The total score for the patient experiences was obtained by summing the 12 items ranges, with higher scores indicating greater experiences agreement. A mean score of 40.267 (SD= 5.029) for patient experiences, with possible scores ranging from 22 to 60 in the present study. Here, good experiences were defined as a score > median=40 on the scale.

Table 1. Experience of clinical research studies in ICU.

| Item | Content | Mean | Standardized errors |
|------|---|-------|---------------------|
| E1 | Overall, the information about the clinical research study was clear. | 1.430 | 2.010 |
| E2 | I was given little opportunity to ask questions about the clinical research study. | 0.820 | 1.315 |
| E3 | It was hard to take in the information about the clinical research study. | 0.913 | 1.444 |
| E4 | I was given enough time to think about whether or not I wanted to take part in the clinical research study. | 1.349 | 1.941 |
| E5 | I felt pressure to take part in the clinical research study. | 0.625 | 1.053 |
| E6 | The person who talked to me about the clinical research study was approachable. | 1.459 | 2.057 |
| E7 | I was informed of the risks and benefits of the clinical research study. | 1.265 | 1.852 |
| E8 | I trusted the person who talked to me about the clinical research study. | 1.439 | 2.022 |
| E9 | Deciding whether or not to take part in the clinical research study was hard. | 0.797 | 1.284 |
| E10 | The person who talked to me about the clinical research study was knowledgeable about it. | 1.413 | 1.994 |
| E11 | I felt comfortable in making a decision about whether to take part in the clinical research study. | 1.404 | 1.986 |
| E12 | I would be willing to take part in clinical research studies in the future. | 1.134 | 1.802 |

Perceptions of clinical research

Items of perceptions of clinical research in the ICU could be seen in Table 2. Response options were missing (=0), strongly disagree (=1), disagree (=2), neither agree nor disagree (=3), agree (=4), and strongly agree (=5). The reliability index of Views on clinical research studies in the ICU in this sample is excellent ($\alpha = 0.8355$).

The total score for the patient perceptions was obtained by summing the 11 items, with higher scores indicating greater perceptions agreement. A mean score of 36.910 (SD= 6.742) for patient perceptions, with possible scores ranging from 0 to 53 in the present study. Here, poor perceptions were defined as a score > median=38 on the scale.

Table 2. Perceptions of clinical research studies in ICU.

| Item | Content | Mean | Standardized errors |
|------|---|-------|---------------------|
| P1 | All ICU patients should take part in clinical research studies, unless a doctor advises against it. | 3.520 | 1.170 |
| P2 | Clinical research in the ICU is important to help other patients in the future. | 4.279 | 0.873 |
| P3 | I assume that treatments given to me on the ICU have already been thoroughly tested in clinical research studies. | 4.058 | 0.994 |
| P4 | I would only want to take part in a clinical research study if my own health might benefit. | 2.544 | 1.256 |
| P5 | When an ICU patient is too ill to decide for themselves, it is acceptable for a member of their family to decide whether the patient should be included in a clinical research study. | 3.654 | 1.170 |
| P6 | When an ICU patient is too ill to decide for themselves, and time is too short to contact a family member, it is acceptable for doctors to decide whether the patient should be included in a clinical research study. | 3.331 | 1.276 |
| P7 | When an ICU patient is too ill to decide for themselves, and there are no known family members to contact, it is acceptable for doctors to decide whether the patient should be included in a clinical research study. | 3.387 | 1.284 |
| P8 | When an ICU patient is too ill to decide for themselves, and there is a known family member, but they cannot be reached, then it is acceptable for doctors to decide whether the patient should be included in a clinical research study. | 3.276 | 1.290 |
| P9 | When an ICU patient is too ill to decide for themselves, it is acceptable for a doctor to ask a family member over the phone for an opinion on whether the patient should be included in the clinical research study. | 3.491 | 1.217 |
| P10 | If I was too ill to make a decision for myself, I would be upset if a doctor had consented on my behalf for me to be included in a clinical research study. | 2.863 | 1.334 |
| P11 | If I was too ill to make a decision for myself, I would be upset if a family member had consented on my behalf for me to be included in a clinical research study. | 2.506 | 1.273 |

Statistical strategies

The statistical analyses in this study involved several steps. First, descriptive analysis is performed to display the frequency and percentage of age group, gender, informed participation, patient experiences, and patient perceptions. Second, independent samples t tests were used to compare means of patient experiences, and patient perceptions between sampled groups. Third, exploratory structural equation modeling (ESEM) was performed to explore potential structures of patient experiences and perceptions with Mplus v7.4. Subsequently, principal component analysis (PCA) in conjunction with varimax rotation with Kaiser's criterion is carried out using the Statistical Package for the Social Sciences (version 20.0; SPSS, Chicago, IL, USA) to explore the structure of patient experiences and perceptions. The Kaiser-Meyer-Olkin (KMO) coefficient and Bartlett's test would be measured to reflect suitable to conduct PCA. KMO values should be between 0 and 1 and larger than 0.7 which indicated the sampling is adequate. Fourth, associations between socioeconomic factors and patient experiences and perceptions were explored with logistic regressions. Finally, confirmatory factor analyses (CFA) were conducted using structural equation model for mediation and moderation models among ICU-days, informed participation, patient experiences, and patient perceptions. Here, goodness-of-fit indices of ESEM and structural equation modeling were chi-square/ degree of freedom (χ^2/df), root mean square error of approximation (RMSEA), Akaike's information criterion (AIC), Bayesian information criterion (BIC), comparative fit index (CFI), Tucker–Lewis Index (TLI), standardized root mean-square residual (SRMR), and coefficient of determination (CD). Fit analyses were completed using Stata 14.0 (Stata Corporation, Texas, USA).

Results

Sample characteristics

The majority of the sample (36.63%) experienced 0 ICU day, followed by 1 day (6.69%), 2 days (11.34%), 3 days (6.10%), 4 days (8.43%), 5 days (5.81%), 6 days (2.91%), 7 days (3.49%), 8 days (2.33%), 14 days (2.03%), 10 days (1.74%), 9 days (1.45%), 13 days (1.45%), and 21 days (1.45%). The average ICU days was 5.217 (± 9.596) ranging from 0 to 70 days. Most of the sample (99.13%) experience 0 year. Among the available sample ($n=344$), 120(34.88%) take part in clinical research for one time, 216(62.79%) for 2 times, 8(2.33%) for 3 times. Among the available sample ($n=324$), 56(17.28%) were young, 133(41.05%) were middle, 135(41.67%) were older adults. Among the available sample ($n=325$), 142(43.69%) were females, 183(56.31%) were males. In table 3, there were no significant ICU-days differences in the case of age groups, gender, informed participation, experiences, and perceptions.

Table 3. Sample characteristics by ICU-days.

| | ICU-days | | | | χ^2 | P-value |
|--|----------|-------|-----------|-------|----------|---------|
| | 0 | | 1 or more | | | |
| | N | % | N | % | | |
| Age (N= 324) | | | | | 1.6401 | 0.440 |
| Young | 22 | 6.79 | 34 | 10.49 | | |
| Middle | 40 | 12.35 | 93 | 28.70 | | |
| Older | 47 | 14.51 | 88 | 27.16 | | |
| Gender (N= 325) | | | | | 1.0226 | 0.312 |
| Female | 51 | 15.69 | 91 | 28.00 | | |
| Male | 56 | 17.23 | 127 | 39.08 | | |
| Informed participation (N= 344) | | | | | 1.4041 | 0.236 |
| No | 77 | 22.38 | 147 | 42.73 | | |
| Yes | 49 | 14.24 | 71 | 20.64 | | |
| Good experiences (N= 120) | | | | | 0.0292 | 0.864 |
| No | 27 | 22.50 | 38 | 31.67 | | |
| Yes | 22 | 18.33 | 33 | 27.50 | | |
| Poor perceptions (N= 344) | | | | | 0.0054 | 0.942 |
| No | 70 | 20.35 | 122 | 35.47 | | |
| Yes | 56 | 16.28 | 96 | 27.91 | | |

Independent samples t tests

In Table 4, there were significant differences regarding item E9 on the basis of ICU-days. Except the item, there were no significant differences regarding items of patient experiences on the basis of gender and ICU-days.

Table 4. Mean-comparison tests of items of patient experiences in gender and ICU days

| Item | Group | Gender | | | ICU days | | |
|------|-------|--------|-------|-------------|----------|-------|-------------|
| | | Female | Male | Differences | 0 | >=1 | Differences |
| E1 | Mean | 4.080 | 4.188 | -0.108 | 3.980 | 4.183 | -0.204 |
| | Obs | 50 | 64 | | 49 | 71 | |
| E2 | Mean | 2.408 | 2.328 | 0.080 | 2.429 | 2.329 | 0.100 |
| | Obs | 49 | 64 | | 49 | 70 | |
| E3 | Mean | 2.542 | 2.762 | -0.220 | 2.766 | 2.629 | 0.137 |
| | Obs | 48 | 63 | | 47 | 70 | |
| E4 | Mean | 3.840 | 4.016 | -0.176 | 3.592 | 4.114 | -0.522 |
| | Obs | 50 | 63 | | 49 | 70 | |
| E5 | Mean | 1.816 | 1.839 | -0.022 | 1.936 | 1.771 | 0.165 |
| | Obs | 49 | 62 | | 47 | 70 | |
| E6 | Mean | 4.080 | 4.266 | -0.186 | 4.041 | 4.282 | -0.241 |
| | Obs | 50 | 64 | | 49 | 71 | |
| E7 | Mean | 3.469 | 3.810 | -0.340 | 3.429 | 3.870 | -0.441 |
| | Obs | 49 | 63 | | 49 | 69 | |
| E8 | Mean | 4.060 | 4.203 | -0.143 | 3.959 | 4.239 | -0.280 |
| | Obs | 50 | 64 | | 49 | 71 | |
| E9 | Mean | 2.408 | 2.175 | 0.234 | 2.625 | 2.114 | 0.511** |
| | Obs | 49 | 63 | | 48 | 70 | |
| E10 | Mean | 3.940 | 4.188 | -0.248 | 3.816 | 4.211 | -0.395 |
| | Obs | 50 | 64 | | 49 | 71 | |
| E11 | Mean | 3.940 | 4.109 | -0.169 | 3.918 | 4.099 | -0.180 |
| | Obs | 50 | 64 | | 49 | 71 | |
| E12 | Mean | 3.413 | 3.789 | -0.376 | 3.595 | 3.677 | -0.082 |
| | Obs | 46 | 57 | | 42 | 65 | |

* ** $p < 0.05$.

In Table 5, there were significant differences regarding item P4 and P10 on the basis of ICU-days. There were significant

differences regarding items P1 to P9 on the basis of informed participation. Except those items, there were no significant differences regarding items of patient perceptions on the basis of gender, ICU-days, and informed participation.

Table 5. Mean-comparison tests of items of patient perceptions in gender, ICU days, and informed participation.

| Item | Group | Gender | | | ICU days | | | Informed participation | | |
|------|-------|--------|-------|-------------|----------|-------|-------------|------------------------|-------|-------------|
| | | Female | Male | Differences | 0 | >=1 | Differences | No | Yes | Differences |
| V1 | Mean | 3.418 | 3.661 | -0.243 | 3.520 | 3.586 | -0.066 | 3.688 | 3.319 | 0.369*** |
| | Obs | 141 | 180 | | 125 | 215 | | 224 | 116 | |
| V2 | Mean | 4.317 | 4.330 | -0.013 | 4.290 | 4.352 | -0.062 | 4.366 | 4.259 | 0.107** |
| | Obs | 142 | 179 | | 124 | 216 | | 224 | 116 | |
| V3 | Mean | 4.134 | 4.123 | 0.011 | 4.033 | 4.167 | -0.134* | 4.197 | 3.966 | 0.232*** |
| | Obs | 142 | 179 | | 123 | 216 | | 223 | 116 | |
| V4 | Mean | 2.556 | 2.564 | -0.008 | 2.823 | 2.431 | 0.392*** | 2.670 | 2.388 | 0.282** |
| | Obs | 142 | 179 | | 124 | 216 | | 224 | 116 | |
| V5 | Mean | 3.704 | 3.709 | -0.005 | 3.710 | 3.690 | 0.020 | 3.795 | 3.509 | 0.286*** |
| | Obs | 142 | 179 | | 124 | 216 | | 224 | 116 | |
| V6 | Mean | 3.479 | 3.298 | 0.180 | 3.352 | 3.381 | -0.029 | 3.455 | 3.207 | 0.248** |
| | Obs | 140 | 181 | | 125 | 215 | | 224 | 116 | |
| V7 | Mean | 3.536 | 3.339 | 0.197 | 3.460 | 3.423 | 0.036 | 3.570 | 3.181 | 0.388*** |
| | Obs | 140 | 180 | | 124 | 215 | | 223 | 116 | |
| V8 | Mean | 3.429 | 3.244 | 0.184 | 3.298 | 3.340 | -0.041 | 3.444 | 3.095 | 0.349*** |
| | Obs | 140 | 180 | | 124 | 215 | | 223 | 116 | |
| V9 | Mean | 3.479 | 3.547 | -0.068 | 3.544 | 3.526 | 0.018 | 3.634 | 3.336 | 0.298*** |
| | Obs | 140 | 181 | | 125 | 215 | | 224 | 116 | |
| V10 | Mean | 2.986 | 2.823 | 0.163 | 3.121 | 2.781 | 0.340** | 2.906 | 2.905 | 0.001 |
| | Obs | 140 | 181 | | 124 | 215 | | 223 | 116 | |
| V11 | Mean | 2.640 | 2.478 | 0.163 | 2.661 | 2.498 | 0.164 | 2.489 | 2.690 | -0.201 |
| | Obs | 139 | 180 | | 124 | 213 | | 221 | 116 | |

* $p < 0.1$, ** $p < 0.05$, *** $p < 0.01$.

Patient experiences of clinical research

Table 6 listed global models fit statistics for models fitting 1, 2, 3, 4, and 5 factors. Only the 5-factor structure was best structural fit of patient experiences ($\chi^2/df = 2.282$, RMSEA=0.061, 90 CI: 0.035-0.087, $p=0.221$, CFI=0.998, TLI=0.990, and SRMR=0.005).

Table 6. Summary of model fit information of patient experiences from ESEM.

| | χ^2 | <i>df</i> | P-Value | χ^2/df | RMSEA | 90 CI | P-Value | CFI | TLI | SRMR |
|-----------------|---------------|-----------|---------------|--------------|--------------|--------------------|--------------|--------------|--------------|--------------|
| 1-factor | 678.653 | 54 | 0.0000 | 12.568 | 0.183 | 0.171-0.196 | 0.000 | 0.929 | 0.913 | 0.046 |
| 2-factor | 259.177 | 43 | 0.0000 | 6.027 | 0.121 | 0.107-0.135 | 0.000 | 0.975 | 0.962 | 0.009 |
| 3-factor | 145.894 | 33 | 0.0000 | 4.421 | 0.100 | 0.084-0.117 | 0.000 | 0.987 | 0.974 | 0.008 |
| 4-factor | 76.885 | 24 | 0.0000 | 3.204 | 0.080 | 0.060-0.100 | 0.007 | 0.994 | 0.983 | 0.004 |
| 5-factor | 36.508 | 16 | 0.0025 | 2.282 | 0.061 | 0.035-0.087 | 0.221 | 0.998 | 0.990 | 0.005 |

df= degrees of freedom

In table 7, PCA was performed by 5 extracted factors with an eigenvalue greater than one accounted for 97.086% of total variance. Each rotated factor was considered to be composed of subtests with loadings bigger than 0.30. KMO measure of sampling adequacy was.961, which indicates adequate sample size for the factor analysis. Bartlett's test of sphericity was significant ($\chi^2 = 8653.876$, $df = 66$, $p < 0.001$). Factor loading after the rotation of each item is shown in Table 1. Accordingly, factor 1 with 3 items (E1, E5, and E9; $\alpha=0.93$), factor 2 with 4 items (E2 and E8; $\alpha=0.84$), factor 3 with 3 items (E3 and E4; $\alpha=0.98$), factor 4 with 3 items (E6, E7, and E10; $\alpha=0.95$), factor 5 with 4 items (E11 and E12; $\alpha=0.94$) were obtained.

According to reference ^{[41][42]}, patient experiences had substantial inter-rater reliability (combined Cohen's Kappa coefficient=0.6064, outcome 0 Kappa =0.9745, outcome 1 Kappa =0.1493, outcome 2 Kappa =0.1539, outcome 3 Kappa =0.3991, outcome 4 Kappa =0.4251, outcome 5 Kappa =0.4143). Thus, the scale could be a good tool to reflect patient experiences among the patients.

Table 7. Item loadings for factor analyses of patient experiences with varimax rotation.

| Item | Factors | | | | |
|------|---------|------|------|------|------|
| | 1 | 2 | 3 | 4 | 5 |
| E1 | .813 | .414 | .215 | .221 | |
| E2 | .424 | .458 | .682 | .281 | .211 |
| E3 | .474 | .490 | .352 | .611 | |
| E4 | .845 | .354 | .226 | .221 | |
| E5 | .361 | .848 | | .254 | |
| E6 | .837 | .365 | .278 | | |
| E7 | .853 | .357 | .230 | | |
| E8 | .833 | .361 | .283 | .219 | |
| E9 | .511 | .714 | .418 | | |
| E10 | .837 | .376 | .244 | .204 | |
| E11 | .833 | .334 | .273 | .212 | .228 |
| E12 | .714 | .215 | .231 | | .594 |

Patient perceptions of clinical research

Table 8 listed global models fit statistics for models fitting 1, 2, 3, and 4 factors. Only the 4-factor structure was best structural fit of patient perceptions ($\chi^2/df = 3.345$, RMSEA=0.083, 90 CI: 0.059-0.107, $p=0.012$, CFI=0.995, TLI=0.984, and SRMR=0.003).

Table 8. Summary of model fit information of patient perceptions of clinical research from ESEM.

| | χ^2 | <i>df</i> | P-Value | χ^2/df | RMSEA | 90 C.I. | P-Value | CFI | TLI | SRMR |
|-----------------|----------|-----------|---------|-------------|-------|-------------|---------|-------|-------|-------|
| 1-factor | 616.610 | 44 | 0.0000 | 14.014 | 0.195 | 0.181-0.208 | 0.000 | 0.930 | 0.913 | 0.048 |
| 2-factor | 209.986 | 34 | 0.0000 | 6.176 | 0.123 | 0.107-0.139 | 0.000 | 0.978 | 0.965 | 0.008 |
| 3-factor | 138.612 | 25 | 0.0000 | 5.544 | 0.115 | 0.097-0.134 | 0.000 | 0.986 | 0.969 | 0.004 |
| 4-factor | 56.859 | 17 | 0.0000 | 3.345 | 0.083 | 0.059-0.107 | 0.012 | 0.995 | 0.984 | 0.003 |

df= degrees of freedom

In table 9, PCA was performed by 5 extracted factors with an eigenvalue greater than one accounted for 77.394% of total variance. Each rotated factor was considered to be composed of subtests with loadings bigger than 0.30. KMO measure of sampling adequacy was .826, which indicates adequate sample size for the factor analysis. Bartlett’s test of sphericity was significant ($\chi^2 = 2141.325$, $df = 55$, $p < 0.001$). Factor loading after the rotation of each item is shown in Table 1. Accordingly, factor 1 with 3 items (P1, P2, and P3; $\alpha = 0.68$), factor 2 with 2 items (P4 and P5; $\alpha = 0.24$), factor 3 with 4 items (P6, P7, P8, and P9; $\alpha = 0.93$), factor 4 with 2 items (P10 and P11; $\alpha = 0.78$) were obtained. Thus, patient perceptions had fair inter-rater reliability (combined Cohen's Kappa coefficient = 0.2321, outcome 0 Kappa = 0.5906, outcome 1 Kappa = 0.2269, outcome 2 Kappa = 0.1066, outcome 3 Kappa = 0.2909, outcome 4 Kappa = 0.2224, outcome 5 Kappa = 0.2897). Thus, the scale could be a good tool to reflect perceptions among the patients.

Table 9. Item loadings for factor analyses of patient perceptions with varimax rotation.

| Item | Factors | | | |
|------|---------|------|-------|------|
| | 1 | 2 | 3 | 4 |
| V1 | .420 | .585 | | |
| V2 | | .224 | .840 | |
| V3 | | .789 | | .216 |
| V4 | | | | .958 |
| V5 | .639 | .338 | -.226 | .228 |
| V6 | .924 | | | |
| V7 | .927 | | | |
| V8 | .880 | | -.208 | |
| V9 | .773 | .225 | | |
| V10 | -.311 | | .817 | |
| V11 | | | .926 | |

Logistic regression

In Table 10, older group had high likelihood of patient perceptions compared with young group (Odds Ratio [OR]: 1.83, 95% confidence interval [CI]: 1.10-3.04). Patients with informed participation in clinical research had low likelihood of poor

patient perceptions than without (OR: 0.46, 95% CI: 0.29-0.74).

Table 10. Associations between socioeconomic factors and patient experiences and perceptions.

| | Good experiences (N=110) | | Poor perceptions (N=319) | |
|------------------------|--------------------------|--------------|--------------------------|--------------|
| | OR | 95% CI | OR | 95% CI |
| Age | | | | |
| Young | 1[reference] | 1[reference] | 1[reference] | 1[reference] |
| Middle | 0.68 | 0.23-2.00 | 1.21 | 0.73-2.01 |
| Older | 1.26 | 0.44-3.55 | 1.83** | 1.10-3.04 |
| Gender | | | | |
| Female | 1[reference] | 1[reference] | 1[reference] | 1[reference] |
| Male | 1.47 | 0.68- 3.18 | 0.75 | 0.49-1.16 |
| ICU-days | | | | |
| 0 | 1[reference] | 1[reference] | 1[reference] | 1[reference] |
| 1 or more | 0.85 | 0.38-1.88 | 0.85 | 0.55-1.32 |
| Informed participation | | | | |
| No | 1[reference] | 1[reference] | 1[reference] | 1[reference] |
| Yes | 0.82 | 0.30-2.27 | 0.46*** | 0.29-0.74 |

* $p < 0.1$, ** $p < 0.05$, *** $p < 0.01$.

Mediation analyses

Regarding mediation analysis, fit statistic in Figure 1 was $\chi^2(0)=0.000$, RMSEA=0.000, 90% CI:0.000-0.000, $p=1.000$, AIC=2036.618, BIC=2081.800, CFI=1.000, TLI=1.000, SRMR=0.000, and CD=0.008. But, all the path coefficients between observed variables were not significant.




Figure 1. Simple mediation analysis.

Regarding moderation analysis, fit statistic in Figure 2 was $\chi^2(0)=0.000$, RMSEA=0.000, 90% CI: 0.000- 0.000, $p=1.000$, AIC=2040.618, BIC=2093.330, CFI=1.000, TLI=1.000, SRMR=0.000, and CD=0.006. But, all the path coefficients between observed variables were not significant.




Figure 2. Simple moderation analysis.

In the structural model, the coefficients of observed variable: informed participation → E (4.092, $p=0.000$) and informed participation → P (-.211, $p=0.003$) were significant. In the measurement model, except the insignificant coefficient of P → P4 (-.050, $p=0.699$), all the other coefficients were significant ($p=.000$). Fit statistic in Figure 3 was $\chi^2(319)=1681.608$, $p > \chi^2=0.000$, RMSEA=0.116, 90% CI: 0.110-0.121, $p_{close}=0.000$, AIC=17998.841, BIC=18315.117, CFI=0.882, TLI =0.870, SRMR=0.076, and CD=0.008.




Figure 3. Informed participation with mediating factors → E mediated by P

In the structural model, the coefficient of informed participation → E (4.087, $p=0.000$) was significant. In the measurement model, except the insignificant coefficient of P → P4 (-.050, $p=0.699$), all the other coefficients were significant ($p=.000$). The correlation coefficient of age ↔ gender was not significant (.011, $p=0.595$). Fit statistic in Figure 4 was $\chi^2(319)=1681.608$, $p > \chi^2=0.000$, RMSEA=0.116, 90% CI: 0.110-0.121, $p_{close}=0.000$, AIC=17998.841, BIC=18315.117, CFI=0.882, TLI =0.870, SRMR=0.076, and CD=0.008.




Figure 4. Informed participation with mediating factors → P mediated by E

In the structural model, the coefficients of informed participation → E (4.092, $p=0.000$) informed participation → P (-.211, $p=0.003$) were significant. In the measurement model, except the insignificant coefficient of P→P4 (-.050, $p=0.699$), all the other coefficients were significant ($p=.000$). The correlation coefficients of ICU-days ↔ age (.007, $p=0.731$), ICU-days ↔ gender (.012, $p=0.376$), age ↔ gender (.011, $p=0.583$) were not significant. Fit statistic in Figure 5 was $\chi^2(319)=1681.608$, $p > \chi^2=0.000$, RMSEA=0.116, 90% CI:0.110-0.121, $p_{close}=0.000$, AIC=18002.841, BIC=18326.648, CFI=0.882, TLI=0.871, SRMR=0.076, and CD=0.006.




Figure 5. Informed participation with moderating factors → E mediated by P

In the structural model, the coefficients of informed participation → E (4.087, $p=0.000$) was significant. In the measurement model, except the insignificant coefficient of P → P4 (-.050, $p=0.699$), all the other coefficients were significant ($p=.000$). The correlation coefficients of ICU-days ↔ age (.007, $p=0.731$), ICU-days ↔ gender (.012, $p=0.376$), age ↔ gender (.011, $p=0.583$) were not significant. Fit statistic in Figure 6 was $\chi^2(319)=1681.608$, $p > \chi^2=0.000$, RMSEA=0.116, 90% CI:0.110-0.121, $p_{close}=0.000$, AIC=18002.841, BIC=18326.648, CFI=0.882, TLI=0.871, SRMR=0.076, and CD=0.006.




Figure 6. Informed participation with moderating factors → P mediated by E

Discussion

Summary

This study reported the factor structures of patient experiences and perceptions of clinical research in ICU. High proportions of good experiences and poor perceptions were reported in the sample. Informed participation had positive association with patient experiences and negative association with patient perspectives into their research. This study did not find significant mediating and moderating effect of socioeconomic factors in the relationship of ICU-days → informed participation, significant mediating and moderating effect of patient perceptions in the relationship of informed participation → patient experiences, and mediating and moderating effect of patient experiences in the relationship of informed participation → perceptions.

Main explanations of key findings

Here are some of the main factors that contribute to patient participation in clinical research: markers of patient interest [43], patient involvement in the development of clinical research work [44], patients' knowledge regarding their illness experience [45], collaborative partnership and social values [46], and transparency and the standard of ethical reporting in nursing clinical research [47].

Poor clinical research could be partially explained by some prior literatures. Most clinical research is considered useless [48]. Limited knowledge on clinical research was observed in community advisory boards [49], clinical nurses [50],

institutional review board members [51], and medical staff in the intensive care unit [52]. Even worse, part of clinical studies is ultimately not fully published in peer-reviewed journals [53] and lack of reproducible effects [54].

Poor perceptions of the patients in ICU could be explained by a large body of studies. Invalid informed consents [55] often preclude adequate understanding of prospective participants in clinical research. In most settings, patients do not understand informed consent what they have signed in clinical research [56]. Regarding patient's perceptions of clinical research, prior studies emphasize the role of clinical trial education [57], transparency and benefits [58]. Moreover, there are cross-cultural gaps of patients' attitudes toward clinical research [59].

Insignificant relationships between patient experiences and perceptions of clinical research could be partially explained by some early studies. Mismatch between patients' expectation and perceived outcomes [60] and contradictory opinions between patients and their legal representatives' concerning enrollment in a scientific study were often observed [61].

Good experiences of the patients in ICU could be explained by a series of studies. Some factors are barriers to high-quality outcomes in a clinical research including cost-effectiveness analysis [62], willingness to participate [63], mendacious informed consent [64], environmental contamination in the ICU wards [65], communication errors [66], pain management [67], medication errors [68][69], selection and information bias [70], poor quality and safety in intensive care [71], and serious drug induced reaction [72]. The patients in the clinical research were uncertain of study outcome and lack of feedback about results at the end of the study [73]. Some factors influencing generalization of outcomes of clinical research have been previously reported. These factors included gender bias in clinical research [74], patients' needs [75], and physicians' burnout in clinical research [76].

To the best knowledge of the author, the findings in this study enriched the process of prior studies. Methodologically, the items of patient perceptions in this study were less than those in an early study, while the dimensions of the scale were more [77]. With respect to sampled participants, this study was performed in adults rather than children and adolescents [78].

To the best knowledge of the author, this study missed some important information like the some prior studies. Compared to a previous study [79], this study did not provide the information of participant retention strategies. Moreover, this study did not provide the information of specific diseases of the patients like reference [80]. Moreover, this study was conducted in ICU rather than clinical research facility [81] or clinical trial unit [82]. Likewise, macro environmental factors like the COVID-19 pandemic [83] were not considered in the clinical research. Simultaneously, clinical research training among medical staff, clinician-scientists, and nurses was not reported.

Limitations

There are three limitations to note in this study. First, test-retest reliability or predictive validity estimates were unable to compute in this cross-sectional study. Second, patients in intensive care units were surveyed regarding informed participation. Therefore, patients' responses in ICU might be not accurate completely. Most patients in ICU lacked decision-making capacity for participation in clinical research [84]. Numerous factors including ICU-acquired pressure

injuries prevalence [85], ICU room configurations [86], heterogeneity [87], nurses' workload [88], medical errors [89], inadequate nutrition [90], and medication errors [91] might influence clinical research among critically ill patients. This is because clinical research can result in inadvertent harm to patients. Third, because the optimization could not converge to a local minimum, some SEMs with components in patient experiences and perceptions could not be analyzed.

Strengths

There are three strengths to note in this study. First, ESEM provided optimal factor structures of patient experiences and perceptions. Second with CFA, ICU-days, age, and gender were identified as limiting to informed participation in clinical research.

Direction for Future research

There were several directions for future research. First, further research on the associations among ICU-days, informed participation, patient experiences, and patient perceptions should consider medical staff and patients' relatives. Second, further study is warranted to determine the factor structures of patient experiences and perceptions of clinical research in ICU in a larger sample.

Policy implications

The findings of this study are crucial and may assist designing, developing, and manipulating clinical research in ICU. In addition, solutions to the challenges for clinical research should be on the basis of understanding of the patient needs for the quality of care. Well-designed clinical research needs to obtain positive patient experiences and perceptions.

Conclusions

The findings in this study may provide a challenge for clinical research in ICU from the angle of patients. Poor statistical relationships among ICU-days, informed participation, patient experiences, and patient perceptions were reported. The empirical outcomes in this study may provide useful insights for subsequent development of new clinical research. These findings suggest that future strategies to enhance the relationship between patient experiences and perceptions of clinical research in ICU may be accomplished through informed participation.

Abbreviations

- ICU: intensive care units
- aOR: Adjusted odds ratio
- 95% CI: 95% confidence interval

Declarations

Funding

This project was funded by XXXXXXXXXXXXX (in Chinese:; Project number:) from 2023 The National Foundation of Philosophy and Social Sciences. The funding body played no role in the study design, data collection, data analysis, data interpretation and manuscript writing.

Ethics approval and consent to participate

The data adopted was from a publicly available survey dataset. All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from all participants before they agreed to participate in the study. Participants were informed that they could leave the study at any time without penalty, and all personal information was kept confidential. Thus, it was not necessary to obtain ethical approval from the institutional review board at the author's institution.

Consent for publication

Not applicable.

Availability of data and material

<https://reshare.ukdataservice.ac.uk/854286/>

Competing Interests

The authors declared no potential conflict of interest with respect to the research, authorship and/or publication of this article.

Authors' contributions

MG designed the study, conceived the statistical analysis, and completed the original version. HYG searched literature, performed Tables and Figures, displayed the statistical outcomes, and participation in the discussion section under the tutorship of MG. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Ming Guan.

Acknowledgement

The author of this paper would like to acknowledge the very helpful comments of two reviewers on the original submission.

References

1. [^]Strüver V, Ali S, Fneish F, Fortwengel G. *Patient Benefit of Clinical Research in Diversely Advanced African Developing Countries*. *Curr Ther Res Clin Exp*. 2021;96:100656. Published 2021 Nov 24. doi:10.1016/j.curtheres.2021.100656
2. [^]Strüver V, Ibeneme SC. *Why are emerging countries popular for clinical research?. S Afr Med J*. 2021;111(5):453-459. Published 2021 Apr 30. doi:10.7196/SAMJ.2021.v111i5.14870
3. [^]Mbo F, Mutombo W, Ngolo D, et al. *How Clinical Research Can Contribute to Strengthening Health Systems in Low Resource Countries*. *Trop Med Infect Dis*. 2020;5(2):48. Published 2020 Mar 29. doi:10.3390/tropicalmed5020048
4. [^]Ise N, Takechi K, Miyamoto T, Ishizawa K, Yanagawa H. *Pharmacy Students' Knowledge and Attitude toward Registration Trials and Clinical Research: A Survey in a Japanese University Hospital*. *Pharmacy (Basel)*. 2017;5(4):67. Published 2017 Dec 11. doi:10.3390/pharmacy5040067
5. [^]Chidambaram AG, Josephson M. *Clinical research study designs: The essentials*. *Pediatr Investig*. 2019;3(4):245-252. Published 2019 Dec 21. doi:10.1002/ped4.12166
6. [^]Nappo SA, Iafrate GB, Sanchez ZM. *Motives for participating in a clinical research trial: a pilot study in Brazil*. *BMC Public Health*. 2013;13:19. Published 2013 Jan 10. doi:10.1186/1471-2458-13-19
7. [^]Courvoisier N, Storari C, Lesage S, et al. *Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study*. *HIV Med*. 2022;23(4):441-447. doi:10.1111/hiv.13259
8. [^]Bass SB, Wolak C, Greener J, et al. *Using perceptual mapping methods to understand gender differences in perceived barriers and benefits of clinical research participation in urban minority HIV+ patients*. *AIDS Care*. 2016;28(4):528-536. doi:10.1080/09540121.2015.1112352
9. [^]Wolak C, Bass SB, Tedaldi E, Vandenburg-Wolf M, Rohrer C. *Minority HIV patients' perceptions of barriers and facilitators to participation in clinical research*. *Curr HIV Res*. 2012;10(4):348-355. doi:10.2174/157016212800792531
10. [^]O'Connor MR, Adem A, Starks H. *East African Perceptions of Barriers/Facilitators for Pediatric Clinical Research Participation and Development of the Inclusive Research Model*. *J Pediatr Nurs*. 2018;42:104-110. doi:10.1016/j.pedn.2018.05.005
11. [^]Hughes TB, Varma VR, Pettigrew C, Albert MS. *African Americans and Clinical Research: Evidence Concerning Barriers and Facilitators to Participation and Recruitment Recommendations*. *Gerontologist*. 2017;57(2):348-358. doi:10.1093/geront/gnv118
12. [^]Diallo BA, Usuf E, Ceesay O, D'Alessandro U, Roca A, Martinez-Alvarez M. *Clinical research on COVID-19: perceptions and barriers to participation in The Gambia*. *BMJ Glob Health*. 2022;7(2):e007533. doi:10.1136/bmjgh-2021-007533
13. [^]Lincoln KD, Chow T, Gaines BF, Fitzgerald T. *Fundamental causes of barriers to participation in Alzheimer's clinical*

- research among African Americans. *Ethn Health*. 2021;26(4):585-599. doi:10.1080/13557858.2018.1539222
14. [^]Robiner WN, Yozwiak JA, Bearman DL, Strand TD, Strasburg KR. Barriers to clinical research participation in a diabetes randomized clinical trial. *Soc Sci Med*. 2009;68(6):1069-1074. doi:10.1016/j.socscimed.2008.12.025
 15. [^]Corneli A, Namey E, Mueller MP, et al. Evidence-Based Strategies for Shortening Informed Consent Forms in Clinical Research. *J Empir Res Hum Res Ethics*. 2017;12(1):14-25. doi:10.1177/1556264616682550
 16. [^]González-Saldivar G, Rodríguez-Gutiérrez R, Viramontes-Madrid JL, et al. Participants' perception of pharmaceutical clinical research: a cross-sectional controlled study. *Patient Prefer Adherence*. 2016;10:727-734. Published 2016 Apr 29. doi:10.2147/PPA.S96021
 17. [^]Bruce MM, Ulrich CM, Kassam-Adams N, Richmond TS. Seriously Injured Urban Black Men's Perceptions of Clinical Research Participation. *J Racial Ethn Health Disparities*. 2016;3(4):724-730. doi:10.1007/s40615-015-0191-y
 18. [^]Kannan V, Wilkinson KE, Varghese M, et al. Count me in: using a patient portal to minimize implicit bias in clinical research recruitment. *J Am Med Inform Assoc*. 2019;26(8-9):703-713. doi:10.1093/jamia/ocz038
 19. [^]Orzechowski M, Woniak K, Timmermann C, Steger F. Normative framework of informed consent in clinical research in Germany, Poland, and Russia. *BMC Med Ethics*. 2021;22(1):53. Published 2021 May 1. doi:10.1186/s12910-021-00622-6
 20. [^]Zahren C, Harvey S, Weekes L, et al. Clinical trials site recruitment optimisation: Guidance from *Clinical Trials: Impact and Quality*. *Clin Trials*. 2021;18(5):594-605. doi:10.1177/17407745211015924
 21. [^]Marathe PA, Tripathi RK, Shetty YC, Kuyare SS, Kamat SK, Thatte UM. Payment for participation in clinical research: Review of proposals submitted to the ethics committees. *Perspect Clin Res*. 2018;9(2):64-69. doi:10.4103/picr.PICR_159_16
 22. [^]Strekalova YA. When Trust Is Not Enough: A Serial Mediation Model Explaining the Effect of Race Identity, eHealth Information Efficacy, and Information Behavior on Intention to Participate in Clinical Research. *Health Educ Behav*. 2018;45(6):1036-1042. doi:10.1177/1090198118757822
 23. [^]Tohid H, Choudhury SM, Agouba S, et al. Perceptions and attitudes to clinical research participation in Qatar. *Contemp Clin Trials Commun*. 2017;8:241-247. Published 2017 Nov 1. doi:10.1016/j.conctc.2017.10.010
 24. [^]Burt T, Dhillon S, Sharma P, et al. PARTAKE survey of public knowledge and perceptions of clinical research in India. *PLoS One*. 2013;8(7):e68666. Published 2013 Jul 16. doi:10.1371/journal.pone.0068666
 25. [^]Mowlabaccus WB, Jodheea-Jutton A. Participant perception, still a major challenge to clinical research in developing countries-A mixed methods study. *PLoS One*. 2020;15(7):e0236563. Published 2020 Jul 30. doi:10.1371/journal.pone.0236563
 26. [^]Lenze EJ, Ramsey A, Brown PJ, et al. Older Adults' Perspectives on Clinical Research: A Focus Group and Survey Study. *Am J Geriatr Psychiatry*. 2016;24(10):893-902. doi:10.1016/j.jagp.2016.07.022
 27. [^]Schäfer F, Quinquis L, Klein M, et al. Attitudes and Expectations of Clinical Research Participants Toward Digital Health and Mobile Dietary Assessment Tools: Cross-Sectional Survey Study. *Front Digit Health*. 2022;4:794908. Published 2022 Mar 9. doi:10.3389/fgdth.2022.794908
 28. [^]González-Saldivar G, Rodríguez-Gutiérrez R, Viramontes-Madrid JL, et al. Participants' perception of pharmaceutical clinical research: a cross-sectional controlled study. *Patient Prefer Adherence*. 2016;10:727-734. Published 2016 Apr

29. doi:10.2147/PPA.S96021
29. [^]Gustad LT, Chaboyer W, Wallis M. ICU patient's transfer anxiety: a prospective cohort study. *Aust Crit Care*. 2008;21(4):181-189. doi:10.1016/j.aucc.2008.07.002
30. [^]Abuatiq A. Patients' and Health Care Providers' Perception of Stressors in the Intensive Care Units. *Dimens Crit Care Nurs*. 2015;34(4):205-214. doi:10.1097/DCC.000000000000121
31. [^]Kollef MH. The intensive care unit as a research laboratory: developing strategies to prevent antimicrobial resistance. *Surg Infect (Larchmt)*. 2006;7(2):85-99. doi:10.1089/sur.2006.7.85
32. [^]Meijers KE, Gustafsson B. Patient's self-determination in intensive care-from an action- and confirmation theoretical perspective. *The intensive care nurse view*. *Intensive Crit Care Nurs*. 2008;24(4):222-232. doi:10.1016/j.iccn.2008.01.003
33. [^]Blackburn GL, Wollner S, Bistran BR. Nutrition support in the intensive care unit: an evolving science. *Arch Surg*. 2010;145(6):533-538. doi:10.1001/archsurg.2010.97
34. [^]Tait RC. Vulnerability in clinical research with patients in pain: a risk analysis. *J Law Med Ethics*. 2009;37(1):59-72. doi:10.1111/j.1748-720X.2009.00351.x
35. [^]Hemminki E, Virtanen JI, Veerus P. Varying ethics rules in clinical research and routine patient care--research ethics committee chairpersons' views in Finland. *Health Res Policy Syst*. 2014;12:15. Published 2014 Mar 25. doi:10.1186/1478-4505-12-15
36. [^]Schatten HT, Gaudio BA, Primack JM, et al. Monitoring, assessing, and responding to suicide risk in clinical research. *J Abnorm Psychol*. 2020;129(1):64-69. doi:10.1037/abn0000489
37. [^]Gilbertson A, Tucker JD, Dubé K, Dijkstra M, Rennie S. Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection. *BMC Med Ethics*. 2021;22(1):169. Published 2021 Dec 28. doi:10.1186/s12910-021-00716-1
38. [^]van der Wilt GJ, Grutters JPC, Maas AHEM, Rolden HJA. Combining value of information analysis and ethical argumentation in decisions on participation of vulnerable patients in clinical research. *BMC Med Ethics*. 2018;19(1):5. Published 2018 Feb 5. doi:10.1186/s12910-018-0245-x
39. [^]Laman M, Pomat W, Siba P, Betuela I. Ethical challenges in integrating patient-care with clinical research in a resource-limited setting: perspectives from Papua New Guinea. *BMC Med Ethics*. 2013;14:29. Published 2013 Jul 26. doi:10.1186/1472-6939-14-29
40. [^]Young, Bridget and Woolfall, Kerry and Frith, Lucy and Gamble, Carrol and Welters, Ingeborg and Paddock, Katie (2021). *The Perspectives Study: From Evidence to Guidance on Patient Recruitment to Clinical Research in Intensive Care Units, 2016-2019*. [Data Collection]. Colchester, Essex: UK Data Service. 10.5255/UKDA-SN-854286
41. [^]George, D., & Mallery, P. (2003). *SPSS for Windows step by step: A simple guide and reference*. 11.0 update (4th ed.). Boston: Allyn & Bacon.
42. [^]Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977 Mar;33(1):159-74. PMID: 843571.
43. [^]Gerber DE, Rasco DW, Skinner CS, et al. Consent timing and experience: modifiable factors that may influence interest in clinical research. *J Oncol Pract*. 2012;8(2):91-96. doi:10.1200/JOP.2011.000335

44. [^]Fairbrother P, McCloughan L, Adam G, et al. *Involving patients in clinical research: the Telescot Patient Panel. Health Expect.* 2016;19(3):691-701. doi:10.1111/hex.12132
45. [^]Brédart A, Marrel A, Abetz-Webb L, Lasch K, Acquadro C. *Interviewing to develop Patient-Reported Outcome (PRO) measures for clinical research: eliciting patients' experience. Health Qual Life Outcomes.* 2014;12:15. Published 2014 Feb 5. doi:10.1186/1477-7525-12-15
46. [^]Nurmi SM, Halkoaho A, Kangasniemi M, Pietilä AM. *Collaborative partnership and the social value of clinical research: a qualitative secondary analysis. BMC Med Ethics.* 2017;18(1):57. Published 2017 Oct 25. doi:10.1186/s12910-017-0217-6
47. [^]Wu Y, Howarth M, Zhou C, Hu M, Cong W. *Reporting of ethical approval and informed consent in clinical research published in leading nursing journals: a retrospective observational study. BMC Med Ethics.* 2019;20(1):94. Published 2019 Dec 5. doi:10.1186/s12910-019-0431-5
48. [^]Ioannidis JP. *Why Most Clinical Research Is Not Useful. PLoS Med.* 2016;13(6):e1002049. Published 2016 Jun 21. doi:10.1371/journal.pmed.1002049
49. [^]Mugenyi L, Mijumbi A, Nanfuka M, et al. *Capacity of community advisory boards for effective engagement in clinical research: a mixed methods study. BMC Med Ethics.* 2021;22(1):165. Published 2021 Dec 15. doi:10.1186/s12910-021-00733-0
50. [^]Yanagawa H, Takai S, Yoshimaru M, Miyamoto T, Katashima R, Kida K. *Nurse awareness of clinical research: a survey in a Japanese University Hospital. BMC Med Res Methodol.* 2014;14:85. Published 2014 Jul 2. doi:10.1186/1471-2288-14-85
51. [^]Mhaskar R, Pathak EB, Wieten S, Guterbock TM, Kumar A, Djulbegovic B. *Those Responsible for Approving Research Studies Have Poor Knowledge of Research Study Design: a Knowledge Assessment of Institutional Review Board Members. Acta Inform Med.* 2015;23(4):196-201. doi:10.5455/aim.2015.23.196-201
52. [^]Johansson L, Knutsson S, Bergbom I, Lindahl B. *Noise in the ICU patient room - Staff knowledge and clinical improvements. Intensive Crit Care Nurs.* 2016;35:1-9. doi:10.1016/j.iccn.2016.02.005
53. [^]Blümle A, Meerpohl JJ, Schumacher M, von Elm E. *Fate of clinical research studies after ethical approval--follow-up of study protocols until publication. PLoS One.* 2014;9(2):e87184. Published 2014 Feb 19. doi:10.1371/journal.pone.0087184
54. [^]Niven DJ, McCormick TJ, Straus SE, et al. *Reproducibility of clinical research in critical care: a scoping review. BMC Med.* 2018;16(1):26. Published 2018 Feb 21. doi:10.1186/s12916-018-1018-6
55. [^]Wisgalla A, Hasford J. *Four reasons why too many informed consents to clinical research are invalid: a critical analysis of current practices. BMJ Open.* 2022;12(3):e050543. Published 2022 Mar 4. doi:10.1136/bmjopen-2021-050543
56. [^]Villamañán E, Ruano M, Fernández-de Uzquiano E, et al. *Informed consent in clinical research; Do patients understand what they have signed?. El consentimiento informado en investigación clínica; ¿Entienden los pacientes lo que firman?. Farm Hosp.* 2016;40(3):209-218. Published 2016 May 1. doi:10.7399/fh.2016.40.3.10411
57. [^]Trantham LC, Carpenter WR, DiMartino LD, et al. *Perceptions of Cancer Clinical Research Among African American Men in North Carolina. J Natl Med Assoc.* 2015;107(1):33-41. doi:10.1016/S0027-9684(15)30007-9

58. [^]Smith SK, Selig W, Harker M, et al. Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey. *PLoS One*. 2015;10(10):e0140232. Published 2015 Oct 14. doi:10.1371/journal.pone.0140232
59. [^]Wu E, Wang T, Lin T, et al. A comparative study of patients' attitudes toward clinical research in the United States and urban and rural China. *Clin Transl Sci*. 2015;8(2):123-131. doi:10.1111/cts.12254
60. [^]Cho HL, Kim SYH, Fitzhugh C, Hsieh M, Tisdale J, Grady C. Motivations and Decision-Making of Adult Sickle Cell Patients in High-Risk Clinical Research. *Biol Blood Marrow Transplant*. 2020;26(6):1225-1232. doi:10.1016/j.bbmt.2020.03.014
61. [^]Pfeilsticker FJDA, Siqueri CASA, Campos NS, et al. Intensive care unit patients' opinion on enrollment in clinical research: A multicenter survey. *PLoS One*. 2020;15(8):e0236675. Published 2020 Aug 13. doi:10.1371/journal.pone.0236675
62. [^]Bartha E, Davidson T, Hommel A, Thorngren KG, Carlsson P, Kalman S. Cost-effectiveness analysis of goal-directed hemodynamic treatment of elderly hip fracture patients: before clinical research starts. *Anesthesiology*. 2012;117(3):519-530. doi:10.1097/ALN.0b013e3182655eb2
63. [^]Raheja D, Davila EP, Johnson ET, Deović R, Paine M, Roupheal N. Willingness to Participate in Vaccine-Related Clinical Trials among Older Adults. *Int J Environ Res Public Health*. 2018;15(8):1743. Published 2018 Aug 14. doi:10.3390/ijerph15081743
64. [^]Choi IS, Choi EY, Lee IH. Challenges in informed consent decision-making in Korean clinical research: A participant perspective. *PLoS One*. 2019;14(5):e0216889. Published 2019 May 23. doi:10.1371/journal.pone.0216889
65. [^]Ong SWX, Lee PH, Tan YK, et al. Environmental contamination in a coronavirus disease 2019 (COVID-19) intensive care unit-What is the risk?. *Infect Control Hosp Epidemiol*. 2021;42(6):669-677. doi:10.1017/ice.2020.1278
66. [^]Williams M, Hevelone N, Alban RF, et al. Measuring communication in the surgical ICU: better communication equals better care. *J Am Coll Surg*. 2010;210(1):17-22. doi:10.1016/j.jamcollsurg.2009.09.025
67. [^]Harvin JA, Kao LS. Pain management in the surgical ICU patient. *Curr Opin Crit Care*. 2020;26(6):628-633. doi:10.1097/MCC.0000000000000773
68. [^]Delavoipière E, Fourage C, Macro M, et al. Déclaration des erreurs médicamenteuses dans les recherches portant sur le médicament: place du pharmacien des essais cliniques? [Medication errors reporting in drug clinical trials: Role of the clinical research pharmacist?]. *Thérapie*. 2021;76(6):735-742. doi:10.1016/j.therap.2021.02.002
69. [^]Rice M, Lear A, Kane-Gill S, Seybert AL, Smithburger PL. Pharmacy Personnel's Involvement in Transitions of Care of Intensive Care Unit Patients: A Systematic Review. *J Pharm Pract*. 2021;34(1):117-126. doi:10.1177/0897190020911524
70. [^]Tripepi G, Jager KJ, Dekker FW, Zoccali C. Selection bias and information bias in clinical research. *Nephron Clin Pract*. 2010;115(2):c94-c99. doi:10.1159/000312871
71. [^]Hewson-Conroy KM, Elliott D, Burrell AR. Quality and safety in intensive care-A means to an end is critical. *Aust Crit Care*. 2010;23(3):109-129. doi:10.1016/j.aucc.2009.12.001
72. [^]Althaus K, Straub A, Häberle H, et al. Heparin-induced thrombocytopenia: Diagnostic challenges in intensive care patients especially with extracorporeal circulation. *Thromb Res*. 2020;188:52-60. doi:10.1016/j.thromres.2020.01.026

73. [^]Keusch F, Rao R, Chang L, Lepkowski J, Reddy P, Choi SW. *Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation.* *Biol Blood Marrow Transplant.* 2014;20(10):1604-1611. doi:10.1016/j.bbmt.2014.06.020
74. [^]Chilet-Rosell E. *Gender bias in clinical research, pharmaceutical marketing, and the prescription of drugs.* *Glob Health Action.* 2014;7:25484. Published 2014 Dec 9. doi:10.3402/gha.v7.25484
75. [^]Jun M, Manns B, Laupacis A, et al. *Assessing the extent to which current clinical research is consistent with patient priorities: a scoping review using a case study in patients on or nearing dialysis.* *Can J Kidney Health Dis.* 2015;2:35. Published 2015 Oct 1. doi:10.1186/s40697-015-0070-9
76. [^]Cagnazzo C, Filippi R, Zucchetti G, et al. *Clinical research and burnout syndrome in Italy - only a physicians' affair?.* *Trials.* 2021;22(1):205. Published 2021 Mar 12. doi:10.1186/s13063-021-05158-z
77. [^]Yessis JL, Kost RG, Lee LM, Coller BS, Henderson DK. *Development of a research participants' perception survey to improve clinical research.* *Clin Transl Sci.* 2012;5(6):452-460. doi:10.1111/j.1752-8062.2012.00443.x
78. [^]Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, et al. *The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).* *Clin Transl Oncol.* 2021;23(12):2489-2496. doi:10.1007/s12094-021-02649-y
79. [^]Browne S, Carter T, Eckes R, et al. *A review of strategies used to retain participants in clinical research during an infectious disease outbreak: The PREVAIL I Ebola vaccine trial experience.* *Contemp Clin Trials Commun.* 2018;11:50-54. Published 2018 Jun 5. doi:10.1016/j.conctc.2018.06.004
80. [^]Evangelista A, Isselbacher EM, Bossone E, et al. *Insights From the International Registry of Acute Aortic Dissection: A 20-Year Experience of Collaborative Clinical Research.* *Circulation.* 2018;137(17):1846-1860. doi:10.1161/CIRCULATIONAHA.117.031264
81. [^]Bayliss K, Prince R, Dewhurst H, Parsons S, Holmes L, Brown P. *Working with public contributors to improve the patient experience at the Manchester Clinical Research Facility: an evaluation of the Experience Based Design approach.* *Res Involv Engagem.* 2017;3:10. Published 2017 Apr 26. doi:10.1186/s40900-017-0059-x
82. [^]Marchesi E, Cagnazzo C, Quattrini I, et al. *How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.* *Clin Sarcoma Res.* 2017;7:4. Published 2017 Feb 28. doi:10.1186/s13569-017-0068-4
83. [^]Gerber DE, Clark VL, Sheffield TY, et al. *Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes.* *JCO Oncol Pract.* 2022;18(1):e98-e107. doi:10.1200/OP.21.00169
84. [^]Goswami R, Moore J, Bruera E, Hui D. *Assessment of the Decision-Making Capacity for Clinical Research Participation in Patients With Advanced Cancer in the Last Weeks of Life.* *J Pain Symptom Manage.* 2020;60(2):400-406. doi:10.1016/j.jpainsymman.2020.02.014
85. [^]Coyer F, Chaboyer W, Lin F, et al. *Pressure injury prevalence in Australian intensive care units: A secondary analysis [published online ahead of print, 2021 Nov 27].* *Aust Crit Care.* 2021;S1036-7314(21)00167-3. doi:10.1016/j.aucc.2021.10.009
86. [^]Joseph A, Joshi R, Mihandoust S, Goel S, Hebbar K, Colman N. *Pediatric Intensive Care Unit (PICU) Patient Room Design: Identifying Safety Risks in Mirrored Rooms Through a Graphical Systems Analysis.* *HERD.* 2022;15(1):189-

206. doi:10.1177/19375867211032921

87. [^]Seifi N, Jafarzadeh Esfahani A, Sedaghat A, et al. *Effect of gut microbiota modulation on feeding tolerance of enterally fed critically ill adult patients: a systematic review*. *Syst Rev*. 2021;10(1):95. Published 2021 Apr 2. doi:10.1186/s13643-021-01633-5
88. [^]Wynne R, Davidson PM, Duffield C, Jackson D, Ferguson C. *Workforce management and patient outcomes in the intensive care unit during the COVID-19 pandemic and beyond: a discursive paper [published online ahead of print, 2021 Jun 28]*. *J Clin Nurs*. 2021;10.1111/jocn.15916. doi:10.1111/jocn.15916
89. [^]Parsons Leigh J, Brundin-Mather R, Whalen-Browne L, et al. *Effectiveness of an Electronic Communication Tool on Transitions in Care From the Intensive Care Unit: Protocol for a Cluster-Specific Pre-Post Trial*. *JMIR Res Protoc*. 2021;10(1):e18675. Published 2021 Jan 8. doi:10.2196/18675
90. [^]Crossfield CL, Russo PL, Bucknall TK. *Enteral nutrition feeding practices by intensive care nurses: A retrospective evaluation [published online ahead of print, 2021 Feb 19]*. *Nurs Crit Care*. 2021;10.1111/nicc.12609. doi:10.1111/nicc.12609
91. [^]Bourne RS, Jennings JK, Panagioti M, Hodkinson A, Sutton A, Ashcroft DM. *Medication-related interventions to improve medication safety and patient outcomes on transition from adult intensive care settings: a systematic review and meta-analysis [published online ahead of print, 2022 Jan 18]*. *BMJ Qual Saf*. 2022;bmjqs-2021-013760. doi:10.1136/bmjqs-2021-013760